MR Imaging Safety Considerations of Gadolinium-Based Contrast Agents: Gadolinium Retention and Nephrogenic Systemic Fibrosis

Research output: Contribution to journalReview articlepeer-review

Abstract

Gadolinium (Gd)-based contrast agents (GBCAs) have revolutionized of MR imaging, enabling physicians to obtain life-saving medical information that often cannot be obtained with unenhanced MR imaging or other imaging modalities. Since regulatory approval in 1988, more than 450 million intravenous GBCA doses have been administered worldwide, with an extremely favorable pharmacologic safety profile. Recent evidence has demonstrated, however, that a small fraction of Gd is retained in human tissues. No direct correlation between Gd retention and clinical effects has been confirmed; however, a subset of patients have attributed various symptoms to GBCA exposure. This review details current knowledge regarding GBCA safety.

Original languageEnglish (US)
Pages (from-to)497-507
Number of pages11
JournalMagnetic resonance imaging clinics of North America
Volume28
Issue number4
DOIs
StatePublished - Nov 2020

Keywords

  • Gadolinium deposition disease
  • Gadolinium retention
  • Gadolinium-based contrast agents
  • MR imaging contrast agent
  • Nephrogenic systemic fibrosis
  • Radiology safety

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'MR Imaging Safety Considerations of Gadolinium-Based Contrast Agents: Gadolinium Retention and Nephrogenic Systemic Fibrosis'. Together they form a unique fingerprint.

Cite this